Sio Gene Therapies is a clinical-stage biopharmaceutical company focused on developing gene therapies for neurodegenerative diseases. Co. has three clinical-stage programs: the AXO-AAV-GM1 program, which is an investigational gene therapy being developed as a potential one-time disease modifying treatment for GM1 gangliosidosis; the AXO-AAV-GM2 program, which is an investigational gene therapy that Co. is developing as a potential one-time disease modifying treatment for GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease); and the AXO-Lenti-PD program, which is an in vivo lentiviral gene therapy investigational product candidate for the treatment of Parkinson's disease. The SIOX stock yearly return is shown above.
The yearly return on the SIOX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SIOX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|